Technical Analysis for TCBP - TC BioPharm (Holdings) plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
20 DMA Resistance | Bearish | 0.81% |
Alert | Time |
---|---|
Possible Inside Day | about 18 hours ago |
60 Minute Opening Range Breakout | about 21 hours ago |
Up 5% | about 21 hours ago |
Gap Down Partially Closed | about 23 hours ago |
Gap Down Closed | about 23 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Solid Tumors Immune System Immunotherapy Cancer Treatment Cancer Immunotherapy Cell Therapy Acute Myeloid Leukemia Cell Biology Treatment Of Acute Myeloid Leukemia T Cells Immunotherapy Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Solid Tumors Immune System Immunotherapy Cancer Treatment Cancer Immunotherapy Cell Therapy Acute Myeloid Leukemia Cell Biology Treatment Of Acute Myeloid Leukemia T Cells Immunotherapy Products
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 20.4 |
52 Week Low | 0.8501 |
Average Volume | 5,995,402 |
200-Day Moving Average | 5.42 |
50-Day Moving Average | 1.48 |
20-Day Moving Average | 1.46 |
10-Day Moving Average | 1.43 |
Average True Range | 0.30 |
RSI (14) | 39.39 |
ADX | 36.77 |
+DI | 46.36 |
-DI | 16.88 |
Chandelier Exit (Long, 3 ATRs) | 2.10 |
Chandelier Exit (Short, 3 ATRs) | 1.96 |
Upper Bollinger Bands | 1.70 |
Lower Bollinger Band | 1.22 |
Percent B (%b) | 0.05 |
BandWidth | 33.48 |
MACD Line | -0.05 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0286 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.51 | ||||
Resistance 3 (R3) | 1.50 | 1.40 | 1.47 | ||
Resistance 2 (R2) | 1.40 | 1.33 | 1.41 | 1.45 | |
Resistance 1 (R1) | 1.32 | 1.29 | 1.36 | 1.33 | 1.43 |
Pivot Point | 1.22 | 1.22 | 1.24 | 1.23 | 1.22 |
Support 1 (S1) | 1.14 | 1.15 | 1.18 | 1.15 | 1.05 |
Support 2 (S2) | 1.04 | 1.11 | 1.05 | 1.03 | |
Support 3 (S3) | 0.96 | 1.04 | 1.02 | ||
Support 4 (S4) | 0.97 |